NewsSource: EClinCloud

EClinCloud Annual Review | 2023, Witnessed with You; 2024, Into a New Journey!

4 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration
Article illustration
Article illustration


2023 has come to a close
Looking back on the past year,
the journey was all the more remarkable because of you.
Every moment we shared together
has been recorded by our time machine—
please take a look!
Article illustration
Article illustration
Article illustration

EClinCloud · 2023


Highlights of the Journey


In the broad evolution of clinical trials, digitalization plays a major driving role. Throughout this year, EClinCloud stayed true to its mission of "bringing effective treatments to patients through technological innovation," moving steadily forward with every milestone clearly in view!




Article illustration


Keyword:

Strengthening Core Capabilities

In 2023, along the path of clinical trial digitalization, EClinCloud remained focused on refining its products and deepening its services.


We increased R&D investment and successively launched 12 systems, including eCOA, CTMS, eTMF, EDC, and RTSM, supporting clinical trials with specialized digital technology;


With continuous iteration and upgrades across features, system performance improved significantly—response time was reduced by 50% and processing capacity increased by 70%, meeting clients' complex operational needs;


At the same time, taking a client-centric approach, we carefully built and delivered a complex functional requirement within just 7 days, earning strong recognition from the client;


Building on this foundation, in 2023 EClinCloud saw new contract volume grow by 172% year-over-year and client count grow by 84% year-over-year, while continuing to add international project experience;


Even more encouragingly, EClinCloud earned widespread recognition through successful case studies—such as supporting a COVID-19 drug in passing CFDI inspection and receiving marketing approval. "Professional, trustworthy, ensuring quality while improving efficiency" has been the consistent feedback from our clients!

Article illustration
Article illustration
Article illustration





Keyword:

Awards and Recognition

Throughout the remarkable chapter of 2023, EClinCloud received repeated recognition.


During the year, EClinCloud successfully held its first User Conference, engaging face-to-face with professionals across related industry sectors to share achievements in the digital transformation and upgrading of clinical research, and receiving genuine praise from major pharmaceutical companies!


Beyond word-of-mouth reputation, we earned tangible awards: in 2023, EClinCloud received 5+ honors in the pharmaceutical and digitalization sectors—representing professional recognition from both the industry and clients—and achieved new breakthroughs with 5+ qualifications and certifications, demonstrating EClinCloud's capabilities in company scale, technological innovation, and software development.


Industry awards received throughout the year include:

  • 2023 Future Healthcare 100 – China Innovative Digital Healthcare Top 100

  • 2023 China Biopharma Frontrunners 100 – Digital Healthcare

  • 2023 Outstanding China Pharmaceutical Digitalization Service Provider

  • 2023 China Pharmaceutical Digitalization Enterprises Top 10

  • Bronze Award, Yangtze River Delta Jujing Sci-Tech Innovation Competition


Enterprise qualifications and certifications obtained include:

  • Innovative Small and Medium-sized Enterprise (SME)

  • Technology-based Small and Medium-sized Enterprise (SME)

  • Double-Soft Enterprise (Software Enterprise and Software Product)

  • National High-Tech Enterprise

  • Specialized, Refined, Differential, and Innovative (SRDI) SME

 Article illustrationArticle illustrationArticle illustrationArticle illustrationArticle illustrationArticle illustration





Keyword:

Innovation and Breakthroughs

Amid the sweeping wave of AI in 2023, EClinCloud also believed that new technologies would enable new approaches, and continued exploring and applying artificial intelligence technologies.


For example, AI-enabled capabilities provide automated detection of blank pages and blurred content in scanned files to improve document processing efficiency, and support document correction to ensure file accuracy and readability.


For document filing, content duplication checks help prevent redundant storage, while automatic filing-folder recommendations based on document content make automated document classification intelligent and convenient.


As another example, using "AI imaging" technology, it intelligently recognizes and automatically intercepts images that do not meet requirements for photo-capture items such as skin and oral cavity images, protecting participant privacy and ensuring clinical trial compliance and data accuracy.

Article illustration




Keyword:

Rooted and United

Through its exploration and growth in 2023, EClinCloud recognized that becoming an industry leader ultimately comes back to corporate culture and its team.


This year, we were not only colleagues at work, but also partners learning together. The "Middle Management Leadership" training became a new classroom for improvement, where everyone studied and discussed together, strengthened professional capabilities, and achieved both individual and team growth.


We also emphasize that our corporate vision is not merely a slogan on the wall, but an inner spark within each of us, always ready to ignite the team's sense of mission and creativity. When it came to team activities, there was truly a wide variety—from afternoon teas to relaxed group outings and the annual company gathering—where everyone exchanged ideas, built rapport, and brought fresh energy to our company culture!

 Article illustrationArticle illustrationArticle illustrationArticle illustrationArticle illustrationArticle illustrationArticle illustration



Article illustration
Article illustration

Memories Forged in 2023

Beginning a New Journey in 2024

In the New Year, Soaring High in the Year of the Dragon

EClinCloud will continue to stay innovation-driven

Market-oriented

Customer-centered

Achieving product upgrades

Internationalization and AI enablement

In 2024

Please continue moving forward with us

Striding toward broader horizons!




About EClinCloud

EClinCloud is a technology company dedicated to clinical R&D. It provides an integrated, interconnected all-in-one clinical trial cloud platform (including eCOA, CTMS, eTMF, EDC, RTSM, RM, and other technology products and solutions, with capabilities such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology). Combining frontier technology with life sciences data, EClinCloud is building a globally leading "patient-centered" SaaS cloud platform supporting clinical evidence to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



Article illustration

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.